Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.

ABSTRACT:

Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) decrease serum urate levels, but whether this translates into prevention of recurrent flares among patients with gout and gout-primary emergency department (ED) visits or hospitalizations is unknown.

Objective

To compare gout flares and cardiovascular events among patients with gout initiating SGLT2is versus dipeptidyl peptidase 4 inhibitors (DPP-4is), another second-line glucose-lowering agent not associated with serum urate levels or cardiovascular risk.

Design

Propensity score-matched, new-user cohort study.

Setting

General population database from 1 January 2014 to 30 June 2022.

Participants

Patients with gout and type 2 diabetes.

Measurements

The primary outcome was recurrent gout

SUBMITTER: McCormick N 

PROVIDER: S-EPMC11921103 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature